- Current report filing (8-K)
12 11월 2008 - 8:20PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of
1934
Date
of
Report (Date of earliest event reported):
November
6, 2008
Targeted
Genetics Corporation
(Exact
name of registrant as specified in its charter)
|
|
|
|
|
Washington
|
|
0-23930
|
|
91-1549568
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification
No.)
|
1100
Olive Way, Suite 100, Seattle, Washington
|
|
98101
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code
|
|
(206) 623-7612
|
(Former
name or former address if changed since last report)
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
|
o
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
|
Item
5.02.
Departure
of Directors or Certain Officers; Election of Directors; Appointment of Certain
Officers; Compensatory Arrangements of Certain
Officers.
On
November 6, 2008, the Board of Directors accepted the resignation of H. Stewart
Parker as the chief executive officer and president of Targeted Genetics
effective November 6, 2008. Ms. Parker remains on the company’s board of
directors. The Board of Directors also accepted the resignation of Barrie J.
Carter as the executive vice president and chief scientific officer of Targeted
Genetics effective November 6, 2008. Ms. Parker managed Targeted Genetics
formation as a wholly owned subsidiary of Immunex Corporation in 1989 and served
as Targeted Genetics’ president, chief executive officer and a director since
that time. Dr. Carter served as Targeted Genetics’ executive vice president
since August 1992 and as Targeted Genetics’ chief scientific officer since
January 2001.
On
November 6, 2008, the Board of Directors appointed B. G. Susan Robinson as
Targeted Genetics’ president and chief executive officer.
B.
G.
Susan Robinson, age 47, has served as Targeted Genetics’ vice president of
business development since December 2001. Ms. Robinson joined Targeted Genetics
in March, 2000 as the company’s senior director of business development. Prior
to joining Targeted Genetics, she was director, business development at Genzyme
Molecular Oncology, a business unit of Genzyme Corporation from 1997 to 2000.
In
her business development roles, she has completed multiple corporate and
academic technology licenses, sponsored research agreements, and product
development collaboration agreements. From 1988 to 1997, Ms. Robinson held
increasingly responsible positions in corporate development and corporate
communications for Immulogic Pharmaceuticals Corporation and T-Cell Sciences,
Inc. (now Celldex). Ms. Robinson is a graduate of Yale
University.
Item
9.01. Financial Statements and
Exhibits.
Exhibits.
99.1
|
Press
Release of Targeted Genetics Corporation dated November 10,
2008
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, as amended, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
|
|
TARGETED
GENETICS CORPORATION
|
|
|
|
Dated:
November 10, 2008
|
By:
|
/s/
DAVID J. POSTON
|
|
David
J. Poston
Vice
President Finance and Chief Financial
Officer
|
INDEX
TO EXHIBITS
Exhibit
Number
|
Description
|
|
|
99.1
|
Press
Release of Targeted Genetics Corporation dated November 10,
2008
|
Tecogen (NASDAQ:TGEN)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Tecogen (NASDAQ:TGEN)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024